

ABSTRACT

New cycloalkanedione derivatives that are serotonin (5-hydroxytryptamine, 5-HT) 5-HT<sub>1A</sub> receptor subtype agonists and, consequently, they are useful in the treatment of pathological states for which an agonist of these receptors is indicated.

They are particularly useful as neuroprotective agents, of special interest in the treatment and prophylaxis of cerebral damage produced by traumatic or ischemic stroke.

In general terms, said cycloalkanedione derivatives correspond to formula I:

